The most talked about and market moving research calls around Wall Street are now in one place. Here are today’s research calls that investors need to know, as compiled by The Fly.

Top 5 Upgrades:

• Oppenheimer upgraded GE Vernova (GEV) to Outperform from Perform with an $855 price target. The company guided to significant upside relative to its previous guidance due to pricing and volume improvements and indicated potential for further upside from factory throughput and operational efficiencies, the firm tells investors in a research note. RBC Capital also upgraded GE Vernova to Outperform from Sector Perform with a price target of $761, up from $630.

• JPMorgan upgraded PepsiCo (PEP) to Overweight from Neutral with a price target of $164, up from $151. The firm believes the company’s “accelerated agenda” of innovation and marketing spending will drive strong productivity savings.

• HSBC upgraded AbbVie (ABBV) to Buy from Hold with a price target of $265, up from $225. The company is seeing growth momentum, and its execution should remain solid, the firm tells investors in a research note.

• Morgan Stanley upgraded Terex (TEX) to Overweight from Equal Weight with a price target of $60, up from $47. The firm cites the company’s “troughing” earnings and improved portfolio for the upgrade.

• Oppenheimer upgraded Dyne Therapeutics (DYN) to Outperform from Perform with a price target of $40, up from $11. The firm notes Dyne has been trading at a discount compared to closest competitor Avidity, mainly due to investor concerns around the myotonic dystrophy type 1 program’s timeline, Phase III powering, and accelerated approval possibility.

Top 5 Downgrades:

• HSBC downgraded Biogen (BIIB) to Reduce from Hold with a price target of $143, down from $144. The company’s “ailing” multiple sclerosis franchise is outweighing its growth elsewhere, the firm tells investors in a research note.

• Jefferies downgraded Emerson (EMR) to Hold from Buy with an unchanged price target of $145. Emerson has executed on its transformation and already provided its updated outlook, notes the firm, which sees limited upside in the near-term given the second half guidance ramp.

• JPMorgan downgraded Noble Corp. (NE) to Neutral from Overweight with a price target of $33, up from $31. The firm retains a cautious sector stance citing upstream spending headwinds, but sees some “idiosyncratic growth opportunities.”

• Jefferies downgraded Regal Rexnord (RRX) to Hold from Buy with a price target of $160, down from $170. The firm says the company’s transformation is taking longer to execute.

• Jefferies downgraded Veralto (VLTO) to Hold from Buy with a price target of $105, down from $125. The firm believes the company’s “stable” demand profile and strong returns are priced into the shares at current levels.